European Hematology Association (EHA) 2022
A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan using PRINCE Trial data versus Ravulizumab and Eculizumab in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
A Real-World Analysis of Healthcare Resource Utilization Among Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Treatment with Ravulizumab
Categorizing Hematological Response to Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Post Hoc Analysis of the Phase 3 PRINCE Study Data
Normalization of Hematologic and QoL Markers in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan and Baseline Hemoglobin at or Above 10 g/dL
Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan Show Improvements in D-dimer Normalization and Decrease in Incidence of Thrombosis
Pegcetacoplan Rapidly Stabilizes Complement Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria Experiencing Hemolysis with Acute Hemoglobin Decreases: PRINCE Trial Post Hoc Analysis
Effect of Pegcetacoplan on Quality of Life in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 PRINCE Study